Shares of ImmunoGen (NASDAQ:IMGN) rose 10% on Friday morning after the company announced a trial of its breast-cancer treatment yielding hopeful results.Immunogen (NASDAQ:IMGN) has potential upside of 11.8% based on a current price of $15.21 and an average consensus analyst price target of $17.Immunogen is currently above its 50-day moving average (MA) of $13.68 and above its 200-day of $12.43.